advertisement
Your Special Attention For IGR 4-3
When does information become medically useful? The role of genetic testing in glaucoma
Parrish RKArchives of Ophthalmology 2002; 120: 1204-1205
No abstract in IGR
'Editorial on myocilin. Concise perspective gives quick information.'
The impact of ocular blood flow in glaucoma
Flammer J, Orgul S, Costa VP, Orzalesi N, Krieglstein GK, Serra LM, Renard JP, Stefansson EProgression in Retinal and Eye Research 2002; 21: 359-393
Abstract No. 827
'Vascular dysregulation is the major cause, not atherosclerosis. Unstable ocular perfusion causes ischemia and reperfusion damage.'
Myocilin and glaucoma: facts and ideas
Tamm ERProgression in Retinal and Eye Research 2002; 21: 395-428
Abstract No. 713
'Myocilin seen from the TM specialist point of view. Conflicting results on MYOC and outflow. What is the function of MYOC?'
Exfoliation syndrome: More than meets the eye
Ritch RActa Ophthalmologica 2002; 80: 465-467
No abstract in IGR
'Review of a global disease (Laps, Navajos, Peruvians, Tunisians). What is the etiology? Infection? Or?'
Health economics, economic evaluation, and glaucoma
Kobelt GJournal of Glaucoma 2002; 11: 531-539
Abstract No. 1024
'Glaucoma health economic studies should not be limited to cost of medication. The impact on Quality of Vision is what counts.'
Myocilin glaucoma
Fingert JH, Stone EM, Sheffield VC, Alward WLMSurvey of Ophthalmology 2002; 47: 547-561
Abstract No. 706
'The myocilin story reviewed. What is the benefit of elucidating glaucoma-genetics?'
Applying evidence-based medicine in ophthalmic practice
Coleman ALAmerican Journal of Ophthalmology 2002; 134: 599-601
No abstract in IGR
'NNT: Number of patients to be treated to prevent progression of one patient. Food for thought.'
The corneal thickness and intraocular pressure story: where are we now?
Lee GA, Khaw PT, Ficker LA, Shah PClinical and Experimental Ophthalmology 2002; 30: 334-337
Abstract No. 731
'CCT revisited. Lots of overlap between normals and glaucoma. Large inter-individual variation.'
The determination of sample size in controlled clinical trials in ophthalmology
Krummenauer F, Dick B, Schwenn O, Pfeiffer NBritish Journal of Ophthalmology 2002; 86: 946-947
No abstract in IGR
'A tutorial text from trial statisticians. Intra-individual versus inter-individual approaches.'
Clinical practice: neovascular glaucoma Neovascular glaucoma
Wertheim M, Broadway DCComprehensive Ophthalmology 2002; 3: 141-152
Abstract No. 877
'Prevention is better than cure. Late presentation, poor outcome.'
Neurobiology of glaucomatous optic neuropathy: Diverse cellular events in neurodegeneration and neuroprotection
Wax MB, Tezel GMolecular Neurobiology. 2002; 26: 45-55
Abstract No. 721
'Cellular mechanisms underlying cell degeneration and glaucoma neuroprotective strategies.'
Gene delivery to the eye using adeno-associated viral vectors
Martin KRG, Klein RL, Quigley HAMethods 2002; 28: 267-275
Abstract No. 957
'A technique for gene delivery.'
Function of nitric oxide in the retina
Oku HNeuro Ophthalmology Japan 2002; 19: 213-21
Abstract No. 720
'Nitric oxide as a player in retinal and ONH ischemia.'
Corticosteroids in uveitis
Rothova AOphthalmology Clinics of North America 2002; 15: 389-394
Abstract No. 882
'Information needed for those who treat uveitic glaucoma.'
Uveitic glaucoma
Kok H, Barton KOphthalmology Clinics of North America 2002; 15: 375-387
Abstract No.880
'Information needed for those who treat uveitic glaucoma.'
Glaucomatous optic neuropathy: mechanisms of disease
Halpern DL, Grosskreutz CLOphthalmology Clinics of North America 2002; 15: 61-68
Abstract No. 717
'To be read with the Wax review. Pathogenesis reviewed.'
Optic disk drusen
Auw-Haedrich C, Staubach F, Witschel HSurvey of Ophthalmology 2002; 47: 515-532
Abstract No. 894
'Optic disk drusen may cause progressive visual field defects. Differential diagnosis with glaucomatous visual field defects.'
